New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
07:06 EDTAGENAgenus appoints Robert Stein as Chief Scientific Officer
Agenus announced the appointment of Robert Stein to the newly-created position of Chief Scientific Officer. The company said, "Stein has had a terrific record in identifying and developing novel therapeutic modalities. He will play a key strategic role as we expand into the immune checkpoint field and in our efforts to establish Agenus as a leader in immuno-oncology."
News For AGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
07:08 EDTAGENAgenus reports Q4 EPS (41c), consensus (16c)
Reports Q4 revenue $1.62M, consensus $620K. Target Milestones for 2015 include: Publication of the Phase 2 data for Prophage in newly diagnosed GBM in a peer reviewed journal. Explore options for the advancement of Prophage for newly diagnosed GBM to a Phase 3 trial. Full Phase 3 data for partner GlaxoSmithKline’s HZ/su shingles vaccine are expected to be presented at a scientific conference and submitted for publication in a peer-reviewed journal. The vaccine contains Agenus’ proprietary QS-21 Stimulon adjuvant. EMA regulatory decision on GlaxoSmithKline’s malaria vaccine candidate RTS,S, which contains Agenus’s QS-21 Stimulon adjuvant. File Investigational New Drug applications for two checkpoint modulator antibody programs as part of our global oncology alliance with Incyte.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use